These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Silvoso GR; Ivey KJ; Butt JH; Lockard OO; Holt SD; Sisk C; Baskin WN; Mackercher PA; Hewett J Ann Intern Med; 1979 Oct; 91(4):517-20. PubMed ID: 314764 [TBL] [Abstract][Full Text] [Related]
3. Risk of gastric injury with enteric- versus nonenteric-coated aspirin. Banoob DW; McCloskey WW; Webster W Ann Pharmacother; 2002 Jan; 36(1):163-6. PubMed ID: 11816246 [TBL] [Abstract][Full Text] [Related]
4. The prevalence of duodenal lesions in patients with rheumatic diseases on chronic aspirin therapy. Lockard OO; Ivey KJ; Butt JH; Silvoso GR; Sisk C; Holt S Gastrointest Endosc; 1980 Feb; 26(1):5-7. PubMed ID: 6965646 [TBL] [Abstract][Full Text] [Related]
5. Twice-daily dosing of enteric-coated aspirin in patients with rheumatic diseases. Bensen WG; Laskin CA; Paton TW; Little HA; Fam AG J Rheumatol; 1979; 6(3):351-9. PubMed ID: 314982 [TBL] [Abstract][Full Text] [Related]
6. [Effects on the gastric mucosa of coated acetylsalicylic acid (Entrophen) and ordinary acetylsalicylic acid: comparative study by endoscopy]. Giroux Y; Archambault A; Farley A; Gosselin D; Orr JM; Marier G; Schipper HL Union Med Can; 1977 Jun; 106(6):841-7. PubMed ID: 883049 [No Abstract] [Full Text] [Related]
7. Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and enteric-coated aspirin. Jaszewski R; Calzada R; Dhar R Dig Dis Sci; 1989 Sep; 34(9):1361-4. PubMed ID: 2766902 [TBL] [Abstract][Full Text] [Related]
9. A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies. Petroski D Am J Gastroenterol; 1986 Jan; 81(1):26-8. PubMed ID: 3942122 [TBL] [Abstract][Full Text] [Related]
10. Reduction in gastric mucosal hemorrhage and ulceration with chronic high-level dosing of enteric-coated aspirin granules two and four times a day. Lanza FL; Rack MF; Wagner GS; Balm TK Dig Dis Sci; 1985 Jun; 30(6):509-12. PubMed ID: 3873326 [TBL] [Abstract][Full Text] [Related]
11. Enteric-coated aspirin and the problem of gastric retention. Baum J J Rheumatol; 1984 Apr; 11(2):250-1. PubMed ID: 6726728 [No Abstract] [Full Text] [Related]
12. Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? Walker J; Robinson J; Stewart J; Jacob S Interact Cardiovasc Thorac Surg; 2007 Aug; 6(4):519-22. PubMed ID: 17669925 [TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal blood loss with low dose (325 mg) plain and enteric-coated aspirin administration. Savon JJ; Allen ML; DiMarino AJ; Hermann GA; Krum RP Am J Gastroenterol; 1995 Apr; 90(4):581-5. PubMed ID: 7717315 [TBL] [Abstract][Full Text] [Related]
14. Enteric-coated pelletized aspirin. Gastrointestinal blood loss and bioavailability. Portek I; Graham G; Fleming A Med J Aust; 1981 Jul; 2(1):39-40. PubMed ID: 6974303 [TBL] [Abstract][Full Text] [Related]